文献速递抗栓抗凝管理药物不良反应与药物警戒

中国房颤患者DOAC、华法林与抗血小板单药治疗的比较结局:一项基于人群的队列研究

Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population-Based Cohort Study.
PubMed 文献 · Drug Saf · 2020-01-01

该研究基于香港电子健康记录,纳入2010–2016年新诊断房颤且CHA2DS2-VASc评分≥2的高危患者,采用倾向性评分匹配比较抗血小板药、华法林与DOAC的缺血性卒中、颅内出血、消化道出血及全因死亡风险。结果显示华法林和DOAC较抗血小板药降低缺血性卒中和全因死亡风险,DOAC较华法林降低颅内出血风险,但抗血小板药处方及华法林管理不佳仍常见。

要点

  • 高危房颤患者中抗血小板药处方和华法林管理不佳仍常见。
  • 华法林和DOAC较抗血小板药降低缺血性卒中和全因死亡风险。
  • DOAC较华法林降低颅内出血风险,各组消化道出血风险相似。

核心结论

  • 在华裔高危房颤患者中,抗血小板药处方及华法林抗凝控制不佳仍常见。
  • DOAC较抗血小板药可能降低缺血性卒中和全因死亡风险,较华法林可能降低颅内出血风险。

研究设计与样本

  • 基于香港电子健康记录的人群队列研究,纳入2010–2016年新诊断房颤患者并随访至2017年。
  • 52,178例高危(CHA2DS2-VASc评分≥2)房颤患者中,27,614例(52.9%)接受抗血栓治疗并纳入分析,采用倾向性评分匹配后以Cox比例风险回归比较结局。

主要发现

  • 2010–2016年间抗血小板药和华法林处方下降,DOAC处方从1%大幅增至32%。
  • 三分之二华法林使用者抗凝控制不佳。
  • 华法林较抗血小板药降低缺血性卒中风险(HR 0.51,95%CI 0.36–0.71)和全因死亡风险(HR 0.47,95%CI 0.39–0.57)。
  • DOAC较抗血小板药降低缺血性卒中风险(HR 0.69,95%CI 0.51–0.94)和全因死亡风险(HR 0.45,95%CI 0.37–0.55)。
  • DOAC较华法林降低颅内出血风险(HR 0.53,95%CI 0.34–0.83),各组消化道出血风险相似。

临床怎么用

  • 高危房颤患者应优先评估抗凝指征,避免以抗血小板药替代抗凝治疗。
  • 使用华法林者需加强抗凝质量控制,DOAC可作为降低颅内出血风险的选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Outcomes associated with suboptimal use of antithrombotic treatments (antiplatelets, warfarin, direct oral anticoagulants [DOACs]) are unclear in Chinese patients with atrial fibrillation (AF). OBJECTIVES: Our objective was to assess the prescription patterns, quality, effectiveness, and safety of antithrombotic treatments. METHODS: This was a population-based cohort study using electronic health records in Hong Kong. Patients newly diagnosed with AF during 2010-2016 were followed up until 2017. Patients at high stroke risk (CHA2DS2-VASc score ≥ 2) and receiving antithrombotic treatments were matched using propensity scoring. We used Cox proportional hazards regression to compare the risks of ischemic stroke, intracranial hemorrhage (ICH), gastrointestinal bleeding (GIB), and all-cause mortality between groups. RESULTS: Of the 52,178 high-risk patients with AF, 27,614 (52.9%) received antithrombotic treatment and were included in the analyses. Between 2010 and 2016, prescribing of antiplatelets and warfarin declined and that of DOACs increased dramatically (from 1 to 32%). Two-thirds of warfarin users experienced poor anticoagulation control. Warfarin and DOACs were associated with lower risks of ischemic stroke (warfarin, hazard ratio [HR] 0.51 [95% confidence interval (CI) 0.36-0.71]; DOACs, HR 0.69 [95% CI 0.51-0.94]) and all-cause mortality (warfarin, HR 0.47 [95% CI 0.39-0.57]; DOACs, HR 0.45 [95% CI 0.37-0.55]) than were antiplatelets. DOACs were associated with a lower risk of ICH than was warfarin (HR 0.53 [95% CI 0.34-0.83]). GIB risks were similar among all groups. CONCLUSION: Antiplatelet prescribing and suboptimal warfarin management remain common in Chinese patients with AF at high risk of stroke. DOAC use may be associated with a lower risk of ischemic stroke and all-cause mortality when compared with antiplatelets and with a lower risk of ICH when compared with warfarin.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Li X, Pathadka S, Man KKC, et al. Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population-Based Cohort Study. Drug Saf. 2020. PMID: 32557348. doi:10.1007/s40264-020-00961-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。